Drugs in ATC Class A06

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Subclasses in ATC: A06 - DRUGS FOR CONSTIPATION

A06A - DRUGS FOR CONSTIPATION

A06 Market Analysis and Financial Projection

The ATC Class A06—Drugs for Constipation encompasses a diverse range of therapies for managing constipation, including osmotic laxatives, bulk-forming agents, peripheral opioid receptor antagonists, and novel biologics. Market dynamics and patent landscapes reflect significant growth driven by increasing prevalence, aging populations, and innovation in drug development.

---

Market Dynamics

Growth Drivers

• Rising Prevalence: Chronic constipation affects ~14% globally, with opioid-induced constipation (OIC) impacting 60% of non-cancer patients on opioids[8][14]. Markets for OIC treatments (valued at $2.51B in 2022) are projected to grow at a 6.2% CAGR through 2029[3].
• Aging Populations: Age-related gastrointestinal motility issues and lifestyle factors (e.g., sedentary habits) fuel demand, particularly in North America, which holds a dominant market share[3][12].
• Pipeline Innovation: New therapies like Lactobacillus gasseri (Phase II)[8] and fast-tracked drugs (e.g., OPT-302 for AMD)[5] highlight R&D momentum.

Key Segments

1. Therapeutic Classes:

   • Laxatives: Bulk-forming agents (e.g., ispaghula) dominate due to safety, while stimulants (e.g., bisacodyl) grow at 6.0% CAGR[20].
   • GC-C Agonists: Linaclotide and plecanatide drive growth in chronic idiopathic constipation (CIC), a $7.8B market in 2019 expanding at 7% CAGR[18].
   • Peripheral Opioid Antagonists: Lubiprostone leads OIC treatments, but naloxegol is gaining traction[3][14].

2. Distribution Channels: Retail pharmacies account for >80% of sales, with online platforms growing rapidly[14].

Regional Trends

• North America: Leads due to high opioid usage and early FDA approvals (e.g., Movantik®)[13].
• Asia-Pacific: Emerging as a growth hotspot, driven by healthcare infrastructure investments[19].

---

Patent Landscape

Strategic IP Developments

• ADC Linker Technologies: Companies like Seagen protect Vedotin® (US 7,659,241), covering linker-cytotoxin combinations used in Adcetris® and Polivy®[2]. Secondary patents focus on formulations and combination therapies[7].
• Novel Compounds:
  • Linaclotide: Patents cover synthesis methods (solid-phase) and stable formulations[4].
  • Simethicone Combinations: EP 1,086,701A claims bisacodyl-simethicone blends to reduce flatulence[10].
  • Halogenated Bi-Cyclic Structures: US 6,414,016B1 describes anti-constipation compositions[16].

Key Players and Licensing

• Licensing: Immunogen’s emtansine (US 5,208,020) licensed to Genentech for Kadcyla®[2].
• Patent Expiries: Movantik® (naloxegol) holds exclusivity until 2032, delaying generics[13].

Emerging Trends

• Bispecific Antibodies: Over 650 patents focus on oncology targets (e.g., PD-1, CTLA-4), reflecting cross-therapeutic innovation[9].
• mRNA Therapeutics: Pfizer and Moderna lead with >200 patents on delivery systems and stability[15].

---

Challenges and Opportunities

Challenge	Opportunity
Generic competition	Biologic and combination therapies
Regulatory hurdles	Fast-track designations for novel drugs
Off-label use (e.g., Avastin)	Precision medicine for subtypes like IBS-C[4]

---

Key Takeaways

1. The constipation treatment market is bifurcated into laxatives (dominant) and newer agents (high-growth).
2. Patent strategies prioritize linker technologies, combination therapies, and lifecycle management.
3. Geography-specific regulatory approvals and aging demographics will shape future growth.

"The ADC patent landscape is dynamic, with companies navigating overlapping IP through strategic licensing and secondary patents." [2][7]

References

1. https://en.wikipedia.org/wiki/ATC_code_A06
2. https://www.fbrice.com.au/ip-news-insights/traversing-a-dynamic-adc-patent-landscape-2/
3. https://www.maximizemarketresearch.com/market-report/global-opioid-induced-constipation-drug-market/25516/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC5491688/
5. https://www.marketsandmarkets.com/Market-Reports/age-related-macular-degeneration-market-37446234.html
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10663041/
7. https://www.patentdocs.org/2018/08/guest-post-antibody-drug-conjugates-the-patent-landscape-for-a-new-class-of-cancer-treatment.html
8. https://www.alliedmarketresearch.com/constipation-treatment-market-A08195
9. https://www.businesswire.com/news/home/20250224366580/en/Bispecific-Antibody-and-Cancer-Patent-Landscape-Analysis-2025-with-IP-Profiles-of-Key-Players-Amgen-Genentech-Roche-GenMab-Janssen-Regeneron-and-Xencor---ResearchAndMarkets.com
10. https://patents.google.com/patent/EP1737537A1/en
11. https://eijppr.com/storage/models/article/5V48DMj2oIDIWTsUKfFWBTiT8YzOvSj6XhVomQdei0ZYmjI1KuMXdlnnCorj/medicines-for-local-therapy-of-wounds-in-the-ukrainian-pharmaceutical-market.pdf
12. https://markets.businessinsider.com/news/stocks/constipation-treatment-market-to-reach-us-22-93-billion-by-2025-escalating-geriatric-population-driving-demand-says-tmr-1002306238
13. https://s28.q4cdn.com/226515471/files/doc_presentations/2022/RedHill-Biopharma-Corporate-Presentation-(June-2022).pdf
14. https://www.biospace.com/constipation-treatment-market-rising-prevalence-of-chronic-constipation
15. https://www.globenewswire.com/news-release/2025/03/11/3040828/0/en/mRNA-Cancer-Therapeutics-Patent-Landscape-Report-and-Forecast-2024-2032-Featuring-Pfizer-Moderna-and-Novartis-with-650-Patents-Combined.html
16. https://patents.google.com/patent/US6414016B1/en
17. https://www.cognitivemarketresearch.com/air-traffic-control--atc--simulator-market-report
18. https://www.transparencymarketresearch.com/chronic-idiopathic-constipation-treatment-market.html
19. https://www.mordorintelligence.com/industry-reports/constipation-treatment-market
20. https://www.factmr.com/report/4801/constipation-laxative-market